News - Cubist Pharmaceuticals, Dificid


Popular Filters

Optimer/Cubist’s Dificid poised to challenge Vancocin usage in C. difficile treatment; report


Less than half of surveyed infectious disease (ID) specialists and only 6% of surveyed internists demonstrated…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalVancocin

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top